EUVIMEDOpdag EUVIMED
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials

Edo J Dongelmans iD, Jordan J Feld, André Boonstra, Sylvia M Brakenhoff iD, David Wong, Colina Yim, Mark Claassen, Pieter Honkoop, Bettina E Hansen, Robert A de Man, Scott Fung iD, Thomas Berg and 3 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18416 ↗

At a glance

Klinische Studie (Phase IV) in Alimentary Pharmacology & Therapeutics, 2025. Written by Edo J Dongelmans and 14 co-authors. Institution: Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands. Major MEDLINE topics: Antiviral Agents, Hepatitis B Core Antigens. Cited 9 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Stichting voor Lever- en Maag-Darm Onderzoek.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Severe flares (ALT ≥ 10×ULN) are a well‐recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these flares is of major importance.

Methods

Data were used from two prospective studies on NA cessation conducted in the Netherlands and Canada. Patients were eligible based on EASL criteria. HBcrAg and anti‐HBc levels were measured at end of treatment (EOT) and week 6 (FUW6). Logistic regression was used to study the association with severe flares.

Results

Seventy‐eight patients were analysed with a mean age of 49 years, 16 (21%) Caucasian and a majority (65%) were treated with Tenofovir. Overall, 22 patients (28%) developed a severe flare, and 29 (37%) patients were retreated. At EOT, higher HBcrAg levels (aOR: 1.97, p = 0.05; ≥ 4log: 47% severe flare vs. < 3log: 19%, p = 0.036), lower anti‐HBc (aOR: 0.29, p = 0.036; < 2log: 50% vs. ≥ 3log: 11%, p = 0.029) and higher HBcrAg/anti‐HBc‐ratio (aOR: 3.17, p = 0.015; ≥ 2: 58% vs. < 1.5: 14%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBsAg. At FUW6, higher HBcrAg (aOR: 2.91, p = 0.035; ≥ 5log: 83%, < 3log: 4%, p < 0.001), lower anti‐HBc (aOR: 0.46, p = 0.29; < 2log: 50% vs. ≥ 3log: 0%, p = 0.003) and higher HBcrAg/anti‐HBc‐ratio (aOR: 2.19, p = 0.048; ≥ 1.75: 52% vs. < 1.75: 8%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBV DNA and ALT.

Conclusion

Higher HBcrAg, lower anti‐HBc and higher HBcrAg/anti‐HBc ratio at EOT and during the first weeks of post‐treatment follow‐up are associated with an increased risk of hepatic flares after NA withdrawal and could therefore potentially be used to select patients eligible for therapy cessation and to identify patients requiring retreatment. Trial Registration: This study was a post hoc and follow‐up study of two previously registered clinical trials (NCT01911156 & NTR7001). No new patients were prospectively included

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsHepatitis B Core AntigensAdultFemaleHumansMaleMiddle AgedCanadaHepatitis B AntibodiesHepatitis B, ChronicNetherlandsProspective StudiesRisk FactorsTenofovir

Author keywords

HBVHBcrAganti‐HBcdiscontinuationflares

Substances

Antiviral AgentsHepatitis B AntibodiesHepatitis B Core AntigensTenofovir

Authors and institutions

  • Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
  • The Toronto Viral Hepatitis Care Network (VIRCAN), Toronto, ON, Canada.
  • Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
  • Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Department of Epidemiology and Biostatistics, Erasmus University Medical Centre, Rotterdam, The Netherlands.

ORCID profiles: Edo J Dongelmans, Sylvia M Brakenhoff, Scott Fung, Florian van Bömmel, Milan J Sonneveld

Funding

  • Stichting voor Lever- en Maag-Darm Onderzoek

Cite

APA

Dongelmans, E. J., Feld, J. J., Boonstra, A., Brakenhoff, S. M., Wong, D., Yim, C., Claassen, M., Honkoop, P., Hansen, B. E., de Man, R. A., Fung, S., Berg, T., van Bömmel, F., Janssen, H. L. A., & Sonneveld, M. J. (2025). Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18416

Vancouver

Dongelmans EJ, Feld JJ, Boonstra A, Brakenhoff SM, Wong D, Yim C, et al. Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18416

BibTeX
@article{Dongelmans2025,
  author = {Dongelmans, Edo J and Feld, Jordan J and Boonstra, André and Brakenhoff, Sylvia M and Wong, David and Yim, Colina and Claassen, Mark and Honkoop, Pieter and Hansen, Bettina E and de Man, Robert A and Fung, Scott and Berg, Thomas and van Bömmel, Florian and Janssen, Harry L A and Sonneveld, Milan J},
  title = {Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18416}
}
Start for free →